ISSN: 2578-6490
Home / Browse Journals & Books / Alzheimers Disease & Dementia / Archive / Volume 1, Issue 1
Select All | |
Short Commentary Pages 34-37
Abstract: It has been almost 4 years since we revealed the solution for the enigma of the so-called "calcium paradox". Our discovery of the involvement of Ca2+/cAMP signaling interaction in the regulation of neurotransmitter release, and neuro protection, was clearly a serendipitous discovery. It has produced new avenues in the understanding of the cellular and molecular mechanisms involved in the pathogenesis of neurological and psychiatric disorders, such as Alzheimer's disease.
| | |
Mini Review Article Pages 29-33
Abstract: The term vascular cognitive impairment designates a heterogenous group of disorders ranging from mild cognitive impairment to full-blown dementia-vascular dementia-resulting from cerebrovascular lesions involving various brain areas. Current clinical criteria show moderate sensitivity (50-56%) and variable specifi city (range 64-98%). The prevalence in autopsy series ranges from 0.03 to 58% (mean 8-15% in Western series, 22-35% in Japan).
SHORT REVIEW ARTICLE Pages 23-28
Abstract: Non-pharmacological therapies have shown to have significant benefits in reducing behavioral psychological symptoms in people with dementia. This is a pilot study to compare the efficacy of two non-pharmacological treatments in people with mild to moderate Alzheimer's Dementia (AD) with behavioral psychological symptoms: hand massage and conversational approach.
RESEARCH ARTICLE Pages 16-22
Abstract: Rensheng Shouwu Capsule (RSSW) is an approved and patented drug of Traditional Chinese Medicine that has been used for years to treat vascular dementia and neural syndrome related to cerebral-vascular ischemia. However, the underlying mechanism of RSSW remains unclear.
Review Article Pages 4-15
Abstract: Alzheimer's disease (AD) is the most devastating age-related dementia, which has no effective treatment. Since the pathological hallmarks of AD brains are Aβ plaques and intra-neuronal tau-containing neurofibrillary tangles, most therapeutic approaches, including immunotherapy, are based on the concept that the accumulation of these proteins produces neuronal damage and death. Alternatively, it has been proposed that reactive species can cause oxidative damage including mitochondrial disruption, contributing to AD initiation and progression.
BRIEF COMMENTARY Pages 1-3
Abstract: It is highly unlikely that James Parkinson (1755-1824), who first described the 'paralysis agitans' in his 'Assay on the Shaking Palsy' in 1817 (years later rebadged by Jean-Martin Charcot as Parkinson's disease), could have imagined that the disorder that today bears his name would become the neurodegenerative disorder that, after Alzheimer's disease, has the largest impact on the elderly population.
Track your Manuscript Status
